Bausch Health Companies Inc.

NYSE:BHC Voorraadrapport

Marktkapitalisatie: US$3.1b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Bausch Health Companies Beheer

Beheer criteriumcontroles 2/4

De CEO Bausch Health Companies' is Tom Appio, benoemd in May2022, heeft een ambtstermijn van 2.42 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 15.88M, bestaande uit 7.4% salaris en 92.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.12% van de aandelen van het bedrijf, ter waarde $ 3.56M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.4 jaar en 8.3 jaar.

Belangrijke informatie

Tom Appio

Algemeen directeur

US$15.9m

Totale compensatie

Percentage CEO-salaris7.4%
Dienstverband CEO2.4yrs
Eigendom CEO0.1%
Management gemiddelde ambtstermijn2.4yrs
Gemiddelde ambtstermijn bestuur8.3yrs

Recente managementupdates

Recent updates

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Sep 19

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Aug 06
Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

2 Red Alerts On Bausch Health Companies

Jul 25

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

May 21
The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

May 07

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Feb 24

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Nov 30

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

Nov 01
Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Sep 24

Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Jul 24
Is Bausch Health Companies (NYSE:BHC) A Risky Investment?

Bausch + Lomb: $2.5bn M&A Deal Shows It Hasn't Learned From Parent's Mistakes

Jul 06

What To Do After Bausch Health Stock Plunged By Nearly 9% Again

Jun 07

Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Apr 18
Bausch Health Companies (NYSE:BHC) Has No Shortage Of Debt

Bausch Health: A Basket Case Of A Business Only A Hedge Fund Can Bail Out

Dec 30

Bausch Health acne lotion Arazlo available in Canada under public drug plans

Dec 22

Bausch Health: Things To Consider Before Investing

Dec 11

Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Nov 10
Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Bausch Health Companies Q3 2022 Earnings Preview

Nov 02

Bausch Health: Long-Term Need To Place Stops For Protection

Sep 28

Bausch Health Companies: Equity Stub Would Benefit From Ambitious Spinoff

Sep 21

Analyse CEO-vergoeding

Hoe is Tom Appio's beloning veranderd ten opzichte van Bausch Health Companies's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

-US$471m

Mar 31 2024n/an/a

-US$455m

Dec 31 2023US$16mUS$1m

-US$592m

Sep 30 2023n/an/a

-US$963m

Jun 30 2023n/an/a

-US$186m

Mar 31 2023n/an/a

-US$357m

Dec 31 2022US$13mUS$1m

-US$225m

Sep 30 2022n/an/a

US$254m

Jun 30 2022n/an/a

US$43m

Mar 31 2022n/an/a

-US$407m

Dec 31 2021US$10mUS$854k

-US$948m

Sep 30 2021n/an/a

-US$1b

Jun 30 2021n/an/a

-US$1b

Mar 31 2021n/an/a

-US$1b

Dec 31 2020US$4mUS$775k

-US$560m

Sep 30 2020n/an/a

-US$2b

Jun 30 2020n/an/a

-US$2b

Mar 31 2020n/an/a

-US$2b

Dec 31 2019US$4mUS$769k

-US$2b

Sep 30 2019n/an/a

-US$616m

Jun 30 2019n/an/a

-US$917m

Mar 31 2019n/an/a

-US$2b

Dec 31 2018US$4mUS$730k

-US$4b

Sep 30 2018n/an/a

-US$3b

Jun 30 2018n/an/a

-US$2b

Mar 31 2018n/an/a

-US$805m

Dec 31 2017US$3mUS$650k

US$2b

Compensatie versus markt: De totale vergoeding ($USD 15.88M ) Tom } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.79M ).

Compensatie versus inkomsten: De vergoeding van Tom is gestegen terwijl het bedrijf verliesgevend is.

CEO

Tom Appio (62 yo)

2.4yrs

Tenure

US$15,878,578

Compensatie

Mr. Thomas J. Appio, also known as Tom, serves as the Chief Executive Officer & Director at Bausch Health Companies Inc. and served as Chief Executive Officer of Pharma Business and served as President & C...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Thomas Appio
CEO & Director2.4yrsUS$15.88m0.12%
$ 3.6m
Seana Carson
Executive VP & General Counsel2.4yrsUS$3.16m0.035%
$ 1.1m
Jean-Jacques Charhon
Chief Financial Officerless than a yeargeen gegevensgeen gegevens
Mirza Dautbegovic
Executive VP & COO2.8yrsgeen gegevens0.035%
$ 1.1m
Kathleen Fitzpatrick
Executive VP and Chief HR & Communications Officer2.8yrsgeen gegevensgeen gegevens
Tage Ramakrishna
Chief Medical Officer and President of R&Dno datageen gegevensgeen gegevens
Jeff Hartness
Executive VP of Market Access4.3yrsgeen gegevensgeen gegevens
Cees Heiman
Senior Vice President of Europe & Canada2.8yrsgeen gegevensgeen gegevens
Donald Pearl
Senior Vice President of Ortho Dermatologicsno datageen gegevensgeen gegevens
Jiny Kim
Senior Vice President of Solta Medical1.8yrsgeen gegevensgeen gegevens
Aimee Lenar
Executive Vice President of US Pharmaless than a yeargeen gegevensgeen gegevens
William Woodfield
Senior VP & Treasurerno datageen gegevensgeen gegevens

2.4yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van BHC wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.4 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Thomas Appio
CEO & Director2.4yrsUS$15.88m0.12%
$ 3.6m
John Paulson
Independent Chairman2.3yrsUS$812.50k0.000060%
$ 1.8k
Robert Power
Independent Director16.2yrsUS$389.55k0.0018%
$ 55.0k
H. Fibiger
Chairman of External Advisory Boardno dataUS$2.00mgeen gegevens
Sarah Kavanagh
Independent Director8.3yrsUS$718.28k0%
$ 0
Robert Lenox
Member of the External Advisory Board15.6yrsgeen gegevensgeen gegevens
Kathleen Clarence-Smith
Member of the External Advisory Board15.6yrsgeen gegevensgeen gegevens
Karoly Nikolich
Member of the External Advisory Board15.6yrsgeen gegevensgeen gegevens
Brett Icahn
Independent Director3.6yrsUS$691.72k0.00020%
$ 6.1k
Amy Wechsler
Independent Director8.3yrsUS$377.50k0.011%
$ 350.6k
Steven Miller
Independent Director3.6yrsUS$381.31k0.031%
$ 939.2k
Christian Garcia
Independent Directorless than a yeargeen gegevensgeen gegevens

8.3yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van BHC wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.3 jaar).